REAL-WORLD USE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN US PATIENTS WITH ANKYLOSING SPONDYLITIS: PERSISTENCE, FACTORS ASSOCIATED WITH DISCONTINUATION, AND DOSING PATTERNS

被引：0

作者：

Dubreuil, M. ^{[1
]}

Walsh, J. A. ^{[2
,3
]}

Deodhar, A. ^{[4
]}

Gensler, L. S. ^{[5
]}

Curtis, J. R. ^{[6
]}

Anjohrin, S. ^{[7
]}

Pilipczuk, O. ^{[8
]}

Tepie, Feudjo M. ^{[9
]}

Beaty, S. ^{[8
]}

Morup, M. ^{[10
]}

Taieb, V ^{[11
]}

Welby, S. ^{[8
]}

机构：

[1] Boston Univ, Sch Med, Boston, MA 02118 USA

[2] Salt Lake City Vet Affairs Hlth, Salt Lake City, UT USA

[3] Univ Utah Hlth, Salt Lake City, UT USA

[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

[6] Univ Alabama Birmingham, Birmingham, AL USA

[7] UCB Pharma, Tallahassee, FL USA

[8] UCB Pharma, Brussels, Belgium

[9] UCB Pharma, Smyrna, GA USA

[10] UCB Pharma, Copenhagen, Denmark

[11] UCB Pharma, Colombes, France

来源：

VALUE IN HEALTH | 2023年 / 26卷 / 06期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

RWD136

引用

页码：S386 / S387

页数：2

共 50 条

[31] Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients
Convertino, Irma
Cazzato, Massimiliano
Tillati, Silvia
Giometto, Sabrina
Gini, Rosa
Valdiserra, Giulia
Cappello, Emiliano
Ferraro, Sara
Bonaso, Marco
Bartolini, Claudia C.
Paoletti, Olga
Lorenzoni, Valentina
Filippi, Matteo
Turchetti, Giuseppe
Cristofano, Michele
Blandizzi, Corrado
Mosca, Marta
Lucenteforte, Ersilia
Tuccori, Marco
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 488 - 489
[32] PREDICTIVE FACTORS FOR SUCCESSFUL BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS DOSE TAPERING IN RHEUMATOID ARTHRITIS
Loh, Min Yi
Jones, Claire J.
Peall, Adrian
Trickey, Jeanette
RHEUMATOLOGY, 2023, 62
[33] The use of conventional disease-modifying anti-rheumatic drugs in established RA
Jurgens, M. S.
Jacobs, J. W. G.
Bijlsma, J. W. J.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2011, 25 (04): : 523 - 533
[34] Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Enrique Machado-Alba, Jorge
Felipe Ruiz, Andres
Enrique Machado-Duque, Manuel
REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2014, 36 (06): : 396 - 401
[35] USE AND COSTS OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS AND BIOLOGIC DMARDS IN AUSTRALIA BETWEEN 2004 AND 2014
Ellen, Donges
Christine, Staatz
Paul, Kubler
Helen, Benham
Samantha, Hollingworth
INTERNAL MEDICINE JOURNAL, 2016, 46 : 9 - 9
[36] Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs
Solomon, Daniel H.
Kremer, Joel M.
Fisher, Mark
Curtis, Jeffrey R.
Furer, Victoria
Harrold, Leslie R.
Hochberg, Marc C.
Reed, George
Tsao, Peter
Greenberg, Jeffrey D.
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2014, 43 (04) : 489 - 497
[37] Use of disease-modifying anti-rheumatic drugs and cardiovascular events in patients with rheumatoid arthritis
Kaminski, Matthew
Shishehbor, Mehdi H.
Gutierrez, Antonio
Amini, Mohammad R.
Coats, Walter
Moghbelli, Meisam
Askari, Arman T.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A370 - A370
[38] The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs
Pombo-Suarez, Manuel
Gomez-Reino, Juan
PHARMACOLOGICAL RESEARCH, 2019, 148
[39] Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated On Non-Biologic Disease-Modifying Anti-Rheumatic Drugs.
Curtis, Jeffrey
Gauthier, Genevieve
Hiscock, Robert
Zhang, Frank
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S782 - S783
[40] Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Jin, Yinzhu
Liu, Jun
Desai, Rishi
Kim, Seoyoung
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3476 - 3479

← 1 2 3 4 5 →